DANIEL DA MOTTA GIRARDI

Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: FEHER, Olavo ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Perioperative chemotherapy with cisplatin (CP) and doxorubicin (DOX) with and without high-dose methotrexate (HDM) in adult osteosarcoma (AOT): Is methotrexate warranted?
    (2015) ROCHA, Lucila Soares Da Silva; NEGRAO, Marcelo Vailati; GIRARDI, Daniel da Motta; CAMARGO, Veridiana Pires De; ALBAN, Luciana Bastos Valente; HOFF, Paulo Marcelo; FEHER, Olavo
  • article 6 Citação(ões) na Scopus
    Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma
    (2017) NEGRAO, Marcelo Vailati; ROCHA, Lucila S. da Silva; GIRARDI, Daniel da Motta; FEHER, Olavo
    Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities. The secondary endpoints included overall survival (OS) and disease-free survival. Despite lower average age (35.0 +/- 12.1 vs. 18.9 +/- 2.1 years), group 2 presented more grade 3-4 thrombocytopenia (0 vs 50%) and mucositis (0 vs 40%), whereas group 1 presented more grade 3-4 neutropenia (43.75 vs 40%). No grade 3-4 renal toxicities occurred. Two grade 5 toxicities occurred in group 2, both after the first HDM cycle. Disease-free survival (4.38 +/- 0.61 vs. 2.3 +/- 0.54 years, P=0.228) and OS (4.70 +/- 0.56 vs 2.52 +/- 0.57 years, P=0.107) were not statistically different, but presented a trend toward better outcomes in group 1. The 4-year OS was 65.6 and 32.8% for groups 1 and 2, respectively. In conclusion, HDM was associated with greater severe and lethal toxicity when added to CP and DOX in AOS. Also, it does not seem to impact on treatment efficacy. These data do not support the use of HDM for the perioperative treatment of AOS.